PBAC's latest decision on Estradiol with progesterone: Recommended with restriction (2025). Considered for Treatment of moderate to severe vasomotor symptoms in postmenopausal women with an intact uterus.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Postmenopausal women with an intact uterus experiencing moderate to severe vasomotor symptoms and estrogen deficiency symptoms.
Therapy area
Women's health
Line of therapy
First-line
Evidence base
Single-arm
Primary endpoint
ORR
Comparator
Estrogel Pro
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated by design.